{"mainPropery":{"diseaseId":10096,"diseaseName":"Hereditary leiomyomatosis and renal cell cancer","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10096/hereditary-leiomyomatosis-and-renal-cell-cancer","synonyms":["LRCC","HLRCC"," Leiomyomatosis and renal cell cancer, hereditary","Multiple cutaneous and uterine leiomyomata","MCUL","Reed's syndrome","Multiple cutaneous leiomyomata","MCL","Familial leiomyomatosis and renal cell cancer","Familial leiomyomatosis cutis et uteri","Familial leiomyomatosis with renal carcinoma","Familial multiple cutaneous leiomyomas"],"synonyms-with-source":[{"name":"LRCC"},{"name":"HLRCC"},{"name":" Leiomyomatosis and renal cell cancer, hereditary","source":"previous disease name"},{"name":"Multiple cutaneous and uterine leiomyomata","source":"GHR, OMIM"},{"name":"MCUL","source":"GHR and OMIM"},{"name":"Reed's syndrome","source":"GHR"},{"name":"Multiple cutaneous leiomyomata","source":"GHR, DermNet NZ, OMIM"},{"name":"MCL","source":"GHR"},{"name":"Familial leiomyomatosis and renal cell cancer","source":"Orphanet"},{"name":"Familial leiomyomatosis cutis et uteri","source":"Orphanet"},{"name":"Familial leiomyomatosis with renal carcinoma","source":"Orphanet"},{"name":"Familial multiple cutaneous leiomyomas","source":"Orphanet"}],"identifiers":[{"identifierType":"OMIM","identifierId":"605839"},{"identifierType":"OMIM","identifierId":"150800"},{"identifierType":"UMLS","identifierId":"C1708350"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":26,"diseaseTypeName":"Kidney and Urinary Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"},{"diseaseTypeId":22,"diseaseTypeName":"Skin Diseases","source":"Orphanet"}],"organizations":[{"resourceID":97,"resourceName":"National Kidney Foundation","abbreviation":"","address1":"30 East 33rd Street","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10016","country":"United States","phone":"212-889-2210","tty":"","tollFree":"800-622-9010","fax":"212-689-9261","email":"info@kidney.org","url":"https://www.kidney.org/","freeText":""},{"resourceID":443,"resourceName":"National Uterine Fibroids Foundation","address1":"P.O. Box 9688","address2":"","address3":"","address4":"","address5":"","city":"Colorado Springs","state":"CO","zip":"80932-0688 ","country":"United States","phone":"719-633-3454 ","tty":"","tollFree":"800-874-7247","fax":"","email":"info@NUFF.org","url":"http://www.nuff.org"},{"resourceID":485,"resourceName":"Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Family Alliance","abbreviation":"","address1":"c/o VHL Family Alliance","address2":"1208 VFW Parkway, Suite 303","address3":"","address4":"","address5":"","city":"Boston","state":"MA","zip":"02132","country":"United States","phone":"617-277-5667 ext. 3","tty":"","tollFree":"800-767-4845 ext. 3 ","fax":"","email":"hlrcc@vhl.org","url":"http://www.hlrccinfo.org/","freeText":""},{"resourceID":505,"resourceName":"The Kidney Foundation of Canada","address1":"700-15 Gervais Drive","address2":"Toronto Ontario M3C 1Y8","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"416-445-0373 ","tty":"","tollFree":"800-387-4474","fax":"416-445-7440 ","email":"kidney@kidney.on.ca","url":"http://www.kidney.on.ca"},{"resourceID":519,"resourceName":"American Kidney Fund, Inc.","abbreviation":"","address1":"11921 Rockville Pike","address2":"Suite 300","address3":"","address4":"","address5":"","city":"Rockville","state":"MD","zip":"20852","country":"United States","phone":"301-881-3052","tty":"","tollFree":"866-300-2900","fax":"","email":"helpline@kidneyfund.org","url":"http://www.kidneyfund.org","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"Online Mendelian Inheritance in Man (OMIM) is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n<a href='http://www.omim.org/605839' target='_blank'>The Online Mendelian Inheritance in Man (OMIM)</a><br /><a href='http://www.omim.org/150800' target='_blank'>The Online Mendelian Inheritance in Man (OMIM)</a><br />","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed/?term=(hereditary+leiomyomatosis+and+renal+cell+cancer)+OR+(multiple+cutaneous+leiomyomata)' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Hereditary leiomyomatosis and renal cell cancer. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://clinicaltrials.gov/ct2/results?term=Hereditary+leiomyomatosis+and+renal+cell+cancer&Search=Search' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Hereditary leiomyomatosis and renal cell cancer. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=hereditaryleiomyomatosisandrenalcellcancer' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Hereditary leiomyomatosis and renal cell cancer. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":336,"resourceId":1154,"resourceName":"RareConnect","descriptionText":"<div style=\"margin-top: 0px; margin-bottom: 0px;\"><a href='https://www.rareconnect.org/en/community/hereditary-leiomyomatosis-and-renal-cell-cancer' target='_blank'>RareConnect</a> has an online community for patients&nbsp;and families with this condition so they can connect with others and share&nbsp;their experiences living with a rare disease.&nbsp;The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).</div>","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":900,"resourceId":1602,"resourceName":"Medscape Reference leiomyoma","descriptionText":"<a href='http://emedicine.medscape.com/article/1057733-overview ' target='_blank'>Medscape Reference</a>Â has a page on leiomyoma that includes some information on hereditary leiomyomatosis and renal cell cancer. You may need to register to view this medical reference page, but registration is free. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1708350' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/hereditary-leiomyomatosis-and-renal-cell-carcinoma/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hlrcc' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1541,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search.php?lng=EN&type_list=clinicalLabs_search_simple_shd&data_id=11495&Disease(s)%20concerned=Leiomyomatosis--familial--with-renal-carcinoma&search=ClinicalLabs_Search_Simple&ChdId=11495&ClinicalLabs_ClinicalLabs_Search_diseaseGroup=leiomyomatosis&ClinicalLabs_ClinicalLabs_Search_diseaseType=Pat&ClinicalLabs_ClinicalLabs_Search_country=NN&ClinicalLabs_ClinicalLabs_Search_GeographicType=null&ClinicalLabs_ClinicalLabs_Search_ClinicalLabsList_Sort=QoS' target='_blank'>Orphanet</a> lists international laboratories offering diagnostic testing for this condition.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1650,"resourceId":500,"resourceName":"Cancer.net","descriptionText":"<a href='https://www.cancer.net/cancer-types/hereditary-leiomyomatosis-and-renal-cell-cancer' target='_blank'>Cancer.net</a> provides oncologist-approved cancer information from the American Society of Clinical Oncology and has information about Hereditary leiomyomatosis and renal cell cancer.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:150800' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Hereditary leiomyomatosis and renal cell cancer. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Hereditary leiomyomatosis and renal cell cancer:<br />\r\n<a href='https://databank.vhl.org/' target='_blank'>MyVHL: Patient Natural History Study</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":2388,"questionText":"What is hereditary leiomyomatosis and renal cell cancer?","answerText":"<strong>Hereditary leiomyomatosis and renal cell cancer (HLRCC)</strong> is a condition that causes benign tumors of smooth muscle tissue in the skin (cutaneous leiomyomas) and in the uterus in females (uterine leiomyomas, or fibroids). The condition also increases the risk of kidney cancer. Signs and symptoms usually begin in adulthood as skin growths appear on the torso, arms, legs, and occasionally on the face. They tend to increase in size and number over time. About 10% to 16% of people with HLRCC develop a type of kidney cancer called renal cell cancer; symptoms of this cancer may include lower back pain, blood in the urine, and/or a mass in the kidney that can be felt by a physician. Some people have no symptoms until the cancer is advanced. HLRCC is caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in the <em><a href=\"http://ghr.nlm.nih.gov/gene=fh\" target=\"_blank\">FH</a></em> gene and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[1497]","dateModified":"2014-01-09T11:54:00"},"basicQuestions":[{"questionId":2183,"questionText":"What are the signs and symptoms of hereditary leiomyomatosis and renal cell cancer?","answerText":"Signs and symptoms of hereditary leiomyomatosis and renal cell cancer (HLRCC) typically begin in adulthood at an average age of 25. The skin growths (cutaneous leiomyomata) appear as skin-colored or light brown bumps on the torso and extremities, and occasionally on the face. They usually increase in size and number with age. They may be more sensitive than the surrounding skin and be painful. Uterine leiomyomata (fibroids) also occur in almost all affected women and tend to be large and numerous. Most women with these have irregular or heavy periods and pelvic pain. A renal tumor occurs in about 10% to 16% of affected individuals (at an average age of 44 years) and may cause blood in the urine, lower back pain, and a palpable mass. Some people with renal cell cancer have no symptoms until the cancer is advanced.[1339][7090]","dateModified":"2014-01-09T12:25:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1339,"authors":"","articleTitle":"Hereditary leiomyomatosis and renal cell cancer","bookWebsiteJournalTitle":"Genetics Home Reference","date":"April 2008","url":"http://ghr.nlm.nih.gov/condition=hereditaryleiomyomatosisandrenalcellcancer","dateAccessed":"2009-06-30T00:00:00"},{"referenceId":7090,"authors":"Manop Pithukpakorn and Jorge R Toro","articleTitle":"Hereditary Leiomyomatosis and Renal Cell Cancer","bookWebsiteJournalTitle":"GeneReviews","date":"November 2, 2010","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1252/","dateAccessed":"2014-01-09T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2184,"questionText":"What causes hereditary leiomyomatosis and renal cell cancer?","answerText":"Hereditary leiomyomatosis and renal cell cancer (HLRCC) is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/FH\" target=\"_blank\">FH</a></em> gene. This gene gives the body instructions for making an enzyme called fumarase which is needed for a series of reactions that lets cells use oxygen and energy (the citric acid cycle, or Krebs cycle). People with HLRCC are born with one mutated copy of the <em>FH</em> gene in each cell. The second copy of the gene in some cells can mutate later on from factors in the environment, such as radiation from the sun or an error during cell division. A mutation can interfere with fumarase's role in the citric acid cycle, which may affect the regulation of oxygen levels in cells. Long-term oxygen deficiency in cells with two mutated copies of the <em>FH</em> gene may contribute to tumors growth and the tendency to develop leiomyomas and/or renal cell cancer.[1339]","dateModified":"2014-01-09T14:24:00","resourceClassificationName":"Cause","references":[{"referenceId":1339,"authors":"","articleTitle":"Hereditary leiomyomatosis and renal cell cancer","bookWebsiteJournalTitle":"Genetics Home Reference","date":"April 2008","url":"http://ghr.nlm.nih.gov/condition=hereditaryleiomyomatosisandrenalcellcancer","dateAccessed":"2009-06-30T00:00:00"}]},{"questionId":7193,"questionText":"How is hereditary leiomyomatosis and renal cell cancer inherited?","answerText":"Hereditary leiomyomatosis and renal cell cancer (HLRCC) is inherited in an <a href=\"http://www.genome.gov/Glossary/index.cfm?id=12\" target=\"_blank\">autosomal dominant</a> pattern, which means that having one mutated copy of the gene in each cell is enough to cause symptoms of the condition. In some cases, an affected person inherits the mutated copy of the gene from an affected parent. Other cases result from new mutations in the gene and that occur for the first time in in the affected individual.[1339]<br />\r\n<br />\r\nWhen an individual with an autosomal dominant condition has children, each child has a 50% (1 in 2) risk to inherit the mutated gene. This is the case regardless of which parent has the condition.","dateModified":"2014-01-09T14:35:00","resourceClassificationName":"Inheritance","references":[{"referenceId":1339,"authors":"","articleTitle":"Hereditary leiomyomatosis and renal cell cancer","bookWebsiteJournalTitle":"Genetics Home Reference","date":"April 2008","url":"http://ghr.nlm.nih.gov/condition=hereditaryleiomyomatosisandrenalcellcancer","dateAccessed":"2009-06-30T00:00:00"}]},{"questionId":2186,"questionText":"How might hereditary leiomyomatosis and renal cell cancer be treated?","answerText":"Skin growths (cutaneous leiomyomas) associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) should be examined by a dermatologist. Treatment of these may include surgery to remove a painful growth; <a href=\"http://www.visualdxhealth.com/cosmetics/cryosurgery.htm\" target=\"_blank\">cryoablation</a> and/or lasers; and/or medications such as <a href=\"http://www.consumerreports.org/health/best-buy-drugs/calcium_blockers.htm\" target=\"_blank\">calcium channel blockers</a>, <a href=\"http://www.mayoclinic.com/print/alpha-blockers/HI00055/METHOD=print\" target=\"_blank\">alpha blockers</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601086.html\" target=\"_blank\">nitroglycerin</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/antidepressants.html\" target=\"_blank\">antidepressants</a>, and/or <a href=\"http://www.consumerreports.org/health/best-buy-drugs/anticonvulsants.htm\" target=\"_blank\">antiepileptic drugs</a> (AEDs), which have been reported to reduce pain.[1353] Uterine fibroids should be evaluated by a gynecologist. These are typically treated in the same manner as those that occur in the general population. However, most women with HLRCC need medication and/or surgical removal of the fibroids (myomectomy) at a younger age. Medications may include <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a685040.html\" target=\"_blank\">gonadotropin-releasing hormone agonists</a> (GnRHa), antihormonal drugs, and pain relievers. <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002915.htm\" target=\"_blank\">Hysterectomy</a> should be performed only when necessary.[1353] Early detection of kidney tumors in HLRCC is important because they grow aggressively. Total <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003001.htm\" target=\"_blank\">nephrectomy </a>may be strongly considered in individuals with a detectable renal mass.[1353]","dateModified":"2014-01-09T15:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1353,"authors":"Pithukpakorn M, Toro JR","articleTitle":"Hereditary Leiomyomatosis and Renal Cell Cancer","bookWebsiteJournalTitle":"GeneReviews","date":"August 6, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hlrcc","dateAccessed":"2015-11-17T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2187,"questionText":"What is the long-term outlook for individuals with hereditary leiomyomatosis and renal cell cancer?","answerText":"Because the cutaneous leiomyomas are difficult to treat, many people choose not to undergo treatment for these.[1353][1354] For some people, surgery to remove them can relieve pain.[1354]\r\nThe uterine fibroids in women with HLRCC can cause severe symptoms. Many affected women have a hysterectomy (removal of the uterus) at a young age (at or before age 30) to relieve the symptoms.[1354][1355]\r\nApproximately 10% to 16% of affected people develop renal cell cancer.[1339] Surgical removal of these cancers often require earlier and more extensive surgery than for other hereditary kidney cancers.[1353] The overall prognosis for an affected person with renal cell cancer depends on the stage of the disease at the time of diagnosis and the overall health of the individual. The survival rate is the highest if the tumor is in the early stages and has not spread outside the kidney.[1356]","dateModified":"2014-01-09T15:54:00","references":[{"referenceId":1339,"authors":"","articleTitle":"Hereditary leiomyomatosis and renal cell cancer","bookWebsiteJournalTitle":"Genetics Home Reference","date":"April 2008","url":"http://ghr.nlm.nih.gov/condition=hereditaryleiomyomatosisandrenalcellcancer","dateAccessed":"2009-06-30T00:00:00"},{"referenceId":1353,"authors":"Pithukpakorn M, Toro JR","articleTitle":"Hereditary Leiomyomatosis and Renal Cell Cancer","bookWebsiteJournalTitle":"GeneReviews","date":"August 6, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hlrcc","dateAccessed":"2015-11-17T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1354,"authors":"Alam NA, Barclay E, Rowan AJ, Tyrer JP, Calonje E, Manek S, Kelsell D, Leigh I, Olpin S, Tomlinson IPM","articleTitle":"","bookWebsiteJournalTitle":"Arch Dermatol","date":"2005","url":"http://archderm.ama-assn.org/cgi/content/full/141/2/199","dateAccessed":"2009-07-06T00:00:00"},{"referenceId":1355,"authors":"Hodge JC, Morton CC","articleTitle":"","bookWebsiteJournalTitle":"Human Molecular Genetics","date":"2007","url":"http://hmg.oxfordjournals.org/cgi/content/full/16/R1/R7","dateAccessed":"2009-07-06T00:00:00"},{"referenceId":1356,"authors":"Dugdale DC","articleTitle":"Renal cell carcinoma","bookWebsiteJournalTitle":"MedlinePlus","date":"2009","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000516.htm","dateAccessed":"2009-07-06T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":12109,"phenoTypeName":"Cutaneous leiomyosarcoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":10521,"phenoTypeName":"Cutaneous leiomyoma","percentRanges":"-"},{"phenoTypeId":13605,"phenoTypeName":"Decreased fumarate hydratase activity","percentRanges":"-"},{"phenoTypeId":7386,"phenoTypeName":"Incomplete penetrance","percentRanges":"-"},{"phenoTypeId":864,"phenoTypeName":"Multiple cutaneous leiomyomas","percentRanges":"-"},{"phenoTypeId":15049,"phenoTypeName":"Renal cell carcinoma","percentRanges":"-"},{"phenoTypeId":10064,"phenoTypeName":"Uterine leiomyoma","percentRanges":"-"},{"phenoTypeId":4301,"phenoTypeName":"Uterine leiomyosarcoma","percentRanges":"-"}],"medicalProducts":[{"productId":51,"genericName":"Sorafenib","tradeName":"Nexavar","tradeLink":"http://www.nexavar-us.com/","manufacturer":"","sponsor":"Bayer Pharmaceutical Corporation","indication":"Treatment of patients with advanced renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/475207-59-1","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607051.html"},{"productId":101,"genericName":"Aldesleukin","tradeName":"ProleukinÂ®","tradeLink":"https://www.proleukin.com/","manufacturer":"","sponsor":"Chiron Corporation","indication":"Treatment of adults (>18 years old) with metastatic renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/Proleukin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692009.html"},{"productId":482,"genericName":"Temsirolimus","tradeName":"ToriselÂ®","tradeLink":"http://torisel.com/","manufacturer":"","sponsor":"Wyeth Pharmaceuticals, Inc.","indication":"Treatment of advanced renal cell carcinoma","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Torisel","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607071.html"}],"EncodedName":"Hereditary_leiomyomatosis_and_renal_cell_cancer"}